Press release
Diabetic Gastroparesis Clinical Trials and Pipeline Analysis 2025: EMA, PDMA, FDA Approvals, Developments, Emerging Therapies, and ROA, MOA and Companies by DelveInsight
(Albany, United States) "Diabetic Gastroparesis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Gastroparesis Market.As per DelveInsight's assessment, globally, Diabetic Gastroparesis pipeline constitutes 6+ key companies continuously working towards developing 8+ Diabetic Gastroparesis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Diabetic Gastroparesis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for sample report @ https://www.delveinsight.com/sample-request/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Diabetic Gastroparesis Pipeline Report:
• Companies across the globe are diligently working toward developing novel Diabetic Gastroparesis treatment therapies with a considerable amount of success over the years.
• Diabetic Gastroparesis companies working in the treatment market are CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharmaceuticals, Takeda, Neurogastrx, Inc, PTC Therapeutics, Theravance Biopharma, Chugai Pharma, GlaxoSmithKline, Processa Pharmaceuticals, and others, are developing therapies for the Diabetic Gastroparesis treatment
• Emerging Diabetic Gastroparesis therapies in the different phases of clinical trials are- CIN-102, Metoclopramide Nasal Spray, Tradipitant, IW-9179, TAK-954, NG101, CNSA-001, velusetrag, GM-611, Camicinal, PCS12852, and others are expected to have a significant impact on the Diabetic Gastroparesis market in the coming years.
• In October 2024, Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company dedicated to developing therapies for gastrointestinal (GI) disorders, especially GIMOTI® (metoclopramide) nasal spray, in collaboration with EVERSANA, a top global commercial services provider for the life sciences sector, announced the presentation of data on GLP-1 users with diabetic gastroparesis treated with GIMOTI at the American College of Gastroenterology.
• In September 2024, The US Food and Drug Administration (FDA) rejected the new drug application (NDA) submitted by Vanda Pharmaceuticals for the use of tradipitant in treating gastroparesis symptoms.
Diabetic Gastroparesis Overview
Diabetic Gastroparesis is a condition that affects the stomach's ability to empty its contents due to nerve damage caused by diabetes. The condition occurs when high blood sugar levels over time damage the vagus nerve, which controls the muscles of the stomach. This results in delayed gastric emptying, causing symptoms like nausea, vomiting, bloating, abdominal pain, and feeling full quickly after eating. It can lead to poor blood sugar control and malnutrition. Treatment focuses on managing blood sugar levels, dietary changes, and medications to improve stomach motility and relieve symptoms.
Get a Free Sample PDF Report to know more about Diabetic Gastroparesis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Diabetic Gastroparesis Drugs Under Different Phases of Clinical Development Include:
• CIN-102: CinDome Pharma, Inc.
• Metoclopramide Nasal Spray: Evoke Pharma
• Tradipitant: Vanda Pharmaceuticals
• IW-9179: Ironwood Pharmaceuticals
• TAK-954: Takeda
• NG101: Neurogastrx, Inc
• CNSA-001: PTC Therapeutics
• velusetrag: Theravance Biopharma
• GM-611: Chugai Pharma
• Camicinal: GlaxoSmithKline
• PCS12852: Processa Pharmaceuticals
Diabetic Gastroparesis Route of Administration
Diabetic Gastroparesis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Diabetic Gastroparesis Molecule Type
Diabetic Gastroparesis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Diabetic Gastroparesis Pipeline Therapeutics Assessment
• Diabetic Gastroparesis Assessment by Product Type
• Diabetic Gastroparesis By Stage and Product Type
• Diabetic Gastroparesis Assessment by Route of Administration
• Diabetic Gastroparesis By Stage and Route of Administration
• Diabetic Gastroparesis Assessment by Molecule Type
• Diabetic Gastroparesis by Stage and Molecule Type
DelveInsight's Diabetic Gastroparesis Report covers around 8+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Diabetic Gastroparesis product details are provided in the report. Download the Diabetic Gastroparesis pipeline report to learn more about the emerging Diabetic Gastroparesis therapies
https://www.delveinsight.com/sample-request/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key companies in the Diabetic Gastroparesis Therapeutics Market include:
Key companies developing therapies for Diabetic Gastroparesis are - Bayer AG, Cipla Limited, Evoke Pharma, Pfizer Inc., Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Salix Pharmaceuticals, Inc., The Takeda Pharmaceutical, Teva Pharmaceutical, and others.
Diabetic Gastroparesis Pipeline Analysis:
The Diabetic Gastroparesis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Gastroparesis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Gastroparesis Treatment.
• Diabetic Gastroparesis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Diabetic Gastroparesis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Gastroparesis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Diabetic Gastroparesis drugs and therapies
https://www.delveinsight.com/sample-request/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Diabetic Gastroparesis Pipeline Market Drivers
• Growing prevalence of diabetes, Unmet medical need, Advancements in drug development, Improved awareness and diagnosis, Regulatory support for innovation, are some of the important factors that are fueling the Diabetic Gastroparesis Market.
Diabetic Gastroparesis Pipeline Market Barriers
• However, Limited effective treatment options, Challenges in drug development, Adverse side effects, High treatment costs, Regulatory challenges, and other factors are creating obstacles in the Diabetic Gastroparesis Market growth.
Scope of Diabetic Gastroparesis Pipeline Drug Insight
• Coverage: Global
• Key Diabetic Gastroparesis Companies: CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharmaceuticals, Takeda, Neurogastrx, Inc, PTC Therapeutics, Theravance Biopharma, Chugai Pharma, GlaxoSmithKline, Processa Pharmaceuticals, and others
• Key Diabetic Gastroparesis Therapies: CIN-102, Metoclopramide Nasal Spray, Tradipitant, IW-9179, TAK-954, NG101, CNSA-001, velusetrag, GM-611, Camicinal, PCS12852, and others
• Diabetic Gastroparesis Therapeutic Assessment: Diabetic Gastroparesis current marketed and Diabetic Gastroparesis emerging therapies
• Diabetic Gastroparesis Market Dynamics: Diabetic Gastroparesis market drivers and Diabetic Gastroparesis market barriers
Request for Sample PDF Report for Diabetic Gastroparesis Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Diabetic Gastroparesis Report Introduction
2. Diabetic Gastroparesis Executive Summary
3. Diabetic Gastroparesis Overview
4. Diabetic Gastroparesis- Analytical Perspective In-depth Commercial Assessment
5. Diabetic Gastroparesis Pipeline Therapeutics
6. Diabetic Gastroparesis Late Stage Products (Phase II/III)
7. Diabetic Gastroparesis Mid Stage Products (Phase II)
8. Diabetic Gastroparesis Early Stage Products (Phase I)
9. Diabetic Gastroparesis Preclinical Stage Products
10. Diabetic Gastroparesis Therapeutics Assessment
11. Diabetic Gastroparesis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Diabetic Gastroparesis Key Companies
14. Diabetic Gastroparesis Key Products
15. Diabetic Gastroparesis Unmet Needs
16 . Diabetic Gastroparesis Market Drivers and Barriers
17. Diabetic Gastroparesis Future Perspectives and Conclusion
18. Diabetic Gastroparesis Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Diabetic Gastroparesis Market https://www.delveinsight.com/report-store/diabetic-gastroparesis-market-size?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
DelveInsight's 'Diabetic Gastroparesis Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Diabetic Gastroparesis Epidemiology https://www.delveinsight.com/report-store/diabetic-gastroparesis-epidemiology?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
DelveInsight's 'Diabetic Gastroparesis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Trending Report:
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-epidemiology-forecast
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Vertigo Market: https://www.delveinsight.com/report-store/vertigo-market
• Calcinosis Cutis Market: https://www.delveinsight.com/report-store/calcinosis-cutis-market
• Healthcare Consulting: https://www.delveinsight.com/consulting
• Healthcare Partner Identification Services: https://www.delveinsight.com/consulting/partner-identification-services
• Molecular Glue Market: https://www.delveinsight.com/report-store/molecular-glues-market-forecast
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/trigeminal-neuralgia-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Gastroparesis Clinical Trials and Pipeline Analysis 2025: EMA, PDMA, FDA Approvals, Developments, Emerging Therapies, and ROA, MOA and Companies by DelveInsight here
News-ID: 4069230 • Views: …
More Releases from DelveInsight Business Research
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics.
DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,…
Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Diabetic
Diabetic Socks Market Dynamics Shaped by Rising Diabetic Population - Persistenc …
The diabetic socks market is gaining significant traction worldwide, driven by the rising prevalence of diabetes and related complications such as diabetic neuropathy and foot ulcers. Designed specifically to cater to the needs of diabetic patients, these socks play a crucial role in foot protection by preventing blistering, reducing moisture accumulation, and providing cushioning to minimize the risk of ulcers. This article delves deeply into the diabetic socks market, exploring…
Leading Element Driving Change in the Diabetic Footwear Market in 2025: Rising D …
Which drivers are expected to have the greatest impact on the over the diabetic footwear market's growth?
The surge in people with diabetes will spur the expansion of the diabetic footwear market in the future. Diabetes, characterised by high blood sugar levels, is a long-term health issue. Diabetic footwear can prevent severe foot-related issues caused by diabetes and offer several advantages such as enhanced blood flow, ample space for the toes,…
Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report.
On the basis of…
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and…
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025.
To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282
Global Diabetic Socks Market: Factors Impacting the Market
The primary factors driving the growth of the global diabetic socks market are increasing…
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be…
